Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
Pharmacomechanical thrombolysis can be particularly effective in mitigating post-thrombotic syndrome (PTS) in younger patients, as demonstrated by data from the ATTRACT trial.
The proportion of risk for alcohol use disorder (AUD) that can be attributed to genetic factors is as high as 60%. This data invokes heritability comparisons to both…
The Centers for Disease Control and Prevention (CDC) has produced a new video for healthcare providers who treat or dispense medications to women of reproductive age. This short…
Alcohol use disorder (AUD) is notoriously difficult to treat, but a new therapeutic option may be on the horizon. Ondansetron, a competitive serotonin type 3 receptor antagonist currently…
Alcohol is the world’s seventh-leading cause of disease burden, researchers found, and is the top risk factor for a variety of diseases in people ages 15-49. Over time,…
Did you know that 2 to 5% of women of reproductive age are affected by a more severe form of premenstrual syndrome (PMS) known as premenstrual dysphoric disorder…
Some of the globe’s leading minds in medical research gathered at this year’s World Stem Cell Summit to discuss the recent developments, breakthroughs, and challenges that have arisen…
